WHAT DO REAL WORLD DATA SAY ABOUT SAFETY AND RESOURCE USE OF ORAL ANTAGONISTS? EARLY ANALYSIS OF NEWLY ANTICOAGULATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS USING EITHER APIXABAN, DABIGATRAN, RIVAROXABAN OR WARFARIN

Xianying Pan,Shital Kamble,Leah Burns,Hugh Kawabata,Jack Mardekian,Cristina Masseria,Kiran Gupta,Hemant Phatak,Gregory Y.H. Lip

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2016）

引用 2|浏览14

暂无评分

摘要

Limited information is available about safety and resource utilization among non-valvular atrial fibrillation (NVAF) patients treated with oral anticoagulants in the real-world setting. This study assessed incidence of all-cause and major bleeding (MB)-related hospitalization and length of stay (LOS

查看译文

关键词

atrial fibrillation patients,atrial fibrillation,oral antagonists,apixaban,non-valvular

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要